RxDoctor Payments Data

David Sas

Pediatric Nephrology · Rochester, MNNPI 1922067776

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $22,341 of the $27,283 with a category attached, or 81.9%. 4 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 45.6% of the total.

$27,283in general payments, 2019–2025

Across 19 payments — averaging $1435.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$12K
  • Novo Nordisk$9K
  • Travere Therapeutics, Inc.$3K
  • Novo Nordisk Health Care AG$3K
$808,174in research payments, 2019–2025

Across 87 payments — averaging $9289.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$593K
  • Alnylam Pharmaceuticals Inc.$201K
  • Novo Nordisk US Research & Development, Inc.$15K

What the payments were for

  • Consulting fees$22,34182%
  • Speaking & faculty fees$4,05015%
  • Travel & lodging$2651%
  • Food & beverage$6252%
  • Education$20%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric nephrology providers in Minnesotato place this figure against a meaningful peer group, so we don't.

Other pediatric nephrology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →